Home » Newsletters » BioWorld

BioWorld

Feb. 11, 2003

View Archived Issues

Johnson & Johnson Buying Scios For $2.4 Billion In Cash

It's official. Scios Inc. is selling out to Johnson & Johnson in a $2.4 billion cash deal. (BioWorld Today) Read More

OSI Acquiring Cell Pathways In Stock Deal Valued At $32M

Wistar Immunologists Construct HIV Adenovirus-Based Vaccine Bypassing Prior Vector Immunity

Biotech Industry Has Nowhere To Go But Up After Dreary Year

Other News To Note

Appointments And Advancements

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...